Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Adhera Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ATRX
Over the counter
8731
https://adherathera.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Adhera Therapeutics Inc
Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ
- May 19th, 2022 1:15 pm
Adhera Therapeutics Names Preeminent Diabetes Pioneer Dr. Jean Buteau to Scientific Advisory Board
- Mar 21st, 2022 1:37 pm
Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace
- Jan 20th, 2022 1:45 pm
Adhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related Disorders
- Nov 22nd, 2021 3:00 pm
Adhera Therapeutics Announces Appointment of Dr. Zahed Subhan to Board of Directors
- Nov 8th, 2021 2:15 pm
Adhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary Inflammation to Portfolio of Target Indications
- Oct 20th, 2021 1:35 pm
Manufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s Disease
- Oct 15th, 2021 2:21 pm
Adhera Receives European Patent Covering MLR-1019 and Derivatives for Treating Dyskinesias
- Oct 4th, 2021 1:15 pm
Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes Drugs
- Sep 13th, 2021 2:28 pm
Adhera Therapeutics Appoints Dr. Andrew Reaume to Board of Directors
- Sep 9th, 2021 1:05 pm
Adhera Therapeutics Signs Exclusive License Agreement with Melior Pharmaceuticals I for New Type 1 Diabetes Drug Candidate
- Aug 24th, 2021 1:20 pm
Adhera Signs Definitive License Agreement with Melior Pharmaceuticals II for New Parkinson’s Disease Drug Candidate
- Jul 29th, 2021 1:00 pm
Adhera Therapeutics Signs Letter of Intent with Melior Pharmaceuticals II to Acquire a New Class of Drug for Parkinson’s Disease
- Jun 7th, 2021 12:45 pm
Scroll